AstraZeneca Plc's (NASDAQ: AZN) supplemental New Drug Application for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and  ...

Sacramento, Calif.-based Sutter Health has joined forces with biopharmaceutical company AstraZeneca to develop a research and innovation collaboration focused on personalized care for ...

FDA approves AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, cutting the risk of death by 27% in the ADRIATIC trial. Imfinzi shows median overall survival of 55.9 months versus ...

After missing the boat for emergency use of COVID-19 vaccines, AstraZeneca has finally pulled the plug on efforts to sell its shot in the U.S. AstraZeneca has decided to withdraw its application ...

LONDON (MarketWatch) -- Anglo-Swedish drug company AstraZeneca said Thursday that its third-quarter net profit rose to $1.59 billion, or $1.01 a share, from $1.23 billion, or 76 cents a share, a ...

AstraZeneca said it and Daiichi Sankyo decided to voluntarily withdraw the marketing authorization application in the European Union for advanced lung-cancer treatment Dato-DXd. This decision ...

AstraZeneca’s Supplemental Biologics License Application for the approval of a self- or caregiver-administered option for Flumist Quadrivalent (Influenza Vaccine Live, Intranasal), a needle-free ...

AstraZeneca has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its experimental precision drug for the treatment of a type of lung cancer, it ...

Danaher and AstraZeneca have formed a partnership to develop diagnostic tools that help clinicians better determine which patients would benefit from precision medicine treatments. The venture ...

AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorisation application in the European Union (EU) voluntarily, intended for datopotamab deruxtecan (Dato-DXd), to treat advanced ...